Odyssey Taps Pharma Veteran Seidel to Guide Autoimmune Pipeline

BOSTON, MA – March 10, 2026 – In a move that signals a significant strategic acceleration, clinical-stage biopharmaceutical company Odyssey Therapeutics has appointed H. Martin Seidel, Ph.D., to its Scientific Advisory Board. The addition of the veteran drug developer, who boasts a formidable track record of translating novel science into approved medicines, reinforces Odyssey's ambitious campaign to develop precisely targeted therapies for autoimmune and inflammatory diseases.

Dr. Seidel's appointment is more than a routine addition to an advisory panel; it represents a calculated move to infuse the company with proven translational and strategic expertise at a pivotal moment. As Odyssey advances its lead programs into mid-stage clinical trials, Seidel's deep experience in navigating the complex path from discovery to market is expected to provide invaluable guidance. The move is widely seen within the industry as a strong validation of Odyssey's scientific platform and its potential to disrupt a highly competitive therapeutic landscape.

A Strategic Reunion of Scientific Minds

The appointment of Dr. Seidel is underscored by his extensive and successful history with key members of Odyssey's leadership. This pre-existing synergy is a critical component of the strategic hire, promising to bypass the typical integration period and allow for immediate, high-impact collaboration.

“Martin brings exceptional depth of experience in drug discovery, translational science and portfolio strategy,” said Gary D. Glick, Ph.D., Founder and CEO of Odyssey Therapeutics. “Martin and I have worked closely together in the past, as have other members of our scientific leadership team... That shared experience gives us deep confidence in his scientific judgment and his ability to help guide our scientific direction.”

Dr. Seidel’s career is a testament to his ability to shepherd complex programs to success. As the current CEO of IFM Therapeutics, a company focused on the innate immune system, he has overseen multiple discovery programs and orchestrated three successful portfolio company exits. His tenure at Novartis Institutes for Biomedical Research (NIBR) was particularly impactful. There, he held senior leadership roles, including Global Head of Strategic Alliances and Head of the Genomics Institute of the Novartis Research Foundation (GNF). During his time leading GNF, Dr. Seidel was instrumental in advancing over 40 clinical candidates, with his oversight contributing to the eventual FDA approval of multiple new molecular entities, including the cancer therapies Zykadia™ and Braftovi™, and the multiple sclerosis drug Mayzent®.

This background in both large pharma and agile biotech, combined with his established rapport with Odyssey's executive team, positions him to provide uniquely effective counsel as the company navigates crucial development and portfolio decisions.

Bolstering a Precision-Focused Pipeline

Odyssey Therapeutics has rapidly established a diverse pipeline aimed at modulating upstream immune pathways to achieve deep and durable remission for patients. The company’s strategy hinges on developing “precision immunomodulators” that target the root drivers of disease without resorting to broad immunosuppression. Dr. Seidel’s expertise aligns perfectly with this sophisticated approach.

The company's lead candidate, OD-07656, is an oral RIPK2 scaffolding inhibitor currently in Phase II trials for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. By disrupting a key signaling node, the therapy aims to quell the inflammatory cascade that drives these debilitating conditions. Beyond IBD, Odyssey’s preclinical pipeline includes an IRAK4 scaffolding inhibitor targeting conditions like atopic dermatitis and hidradenitis suppurativa, as well as protein therapeutics for diseases such as systemic lupus erythematosus and asthma.

Dr. Seidel’s own work has centered on similar biological territory. His leadership at IFM Therapeutics, which targets the innate immune system, gives him a profound understanding of the pathways Odyssey is pursuing. This direct experience in target selection and translational science for inflammatory and autoimmune diseases will be critical as Odyssey advances its programs.

“Odyssey is working in an area of biology that is particularly ripe for drug discovery, and the breadth of scientific capabilities the team has assembled is unusual in today’s biotech landscape,” Dr. Seidel stated. “My work has long focused on applying cutting-edge science to drug discovery, and I look forward to contributing my experience across target selection and translation as Odyssey advances its programs toward the clinic.”

A Competitive Edge in a Crowded Field

The therapeutic area for autoimmune and inflammatory diseases is one of the most competitive and lucrative in the biopharmaceutical industry. The market is dominated by blockbuster drugs like TNF inhibitors and JAK inhibitors, and dozens of companies are racing to develop the next generation of therapies with improved efficacy, safety, and durability. For a relatively young company like Odyssey, which was founded in 2021, differentiation is key to survival and success.

In this intense “talent war,” attracting a leader of Dr. Seidel’s caliber is a significant competitive advantage. High-profile appointments are often interpreted by investors and potential partners as a strong signal of a company's internal confidence and the validity of its underlying science. It demonstrates that seasoned experts, who have their pick of advisory roles, see a compelling opportunity and a high probability of success. This can be instrumental in securing future funding, attracting further top-tier talent, and establishing credibility in a field where novel mechanisms face intense scrutiny.

Odyssey's strategy of targeting upstream pathways like RIPK2 and IRAK4 is designed to create a new class of medicines, but it also carries inherent development risks. Dr. Seidel's experience in successfully navigating such risks at Novartis and IFM—evaluating targets, designing translational studies, and making tough portfolio decisions—provides Odyssey with a seasoned guide to de-risk its innovative pipeline and optimize its path to market.

The Power of a Specialized Advisory Board

Dr. Seidel joins an already distinguished Scientific Advisory Board, and his appointment serves to round out its collective expertise. The existing board includes academic powerhouses like Chair Stephen Blacklow, M.D., Ph.D., of Harvard, a leading expert in the molecular mechanisms of signal transduction; Richard Flavell, Ph.D., F.R.S., of Yale, a world-renowned immunobiologist; and Seth Masters, Ph.D., a specialist in inflammasomes and autoinflammatory disease. While these members provide deep, foundational scientific knowledge, Dr. Seidel brings a crucial translational and commercial-facing perspective.

His role will be to bridge the gap between cutting-edge academic science and the pragmatic realities of drug development. His experience executing over 70 strategic deals at Novartis, with a total value exceeding $8 billion, adds a layer of business acumen and strategic foresight that is vital for a clinical-stage company planning its future. This fusion of deep science and proven development strategy creates a formidable brain trust to guide Odyssey. The enhanced board is now better equipped to not only validate scientific targets but also to help shape a clinical and regulatory strategy that maximizes the potential for success in a global marketplace, ultimately accelerating the delivery of novel treatments to patients in need.